Ultragenyx Pharmaceutical (RARE) Cash from Investing Activities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Cash from Investing Activities data on file, last reported at -$49.0 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 140.83% year-over-year to -$49.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.0 million (up 785.66% YoY) and the FY2025 annual result came in at $236.0 million, up 1411.11% from the prior year.
• Cash from Investing Activities climbed to -$49.0 million in Q1 2026 per RARE's latest filing, from -$72.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $120.0 million in Q1 2025 and bottomed at -$275.5 million in Q3 2024.
• The 5-year median for Cash from Investing Activities is $64.3 million (2023), against an average of $2.7 million.
• The widest annual swing landed in 2023, when Cash from Investing Activities jumped 397.91%; it then tumbled 528.5% in 2024.
• Tracing RARE's Cash from Investing Activities over 5 years: stood at -$171.6 million in 2022, then surged by 37.64% to -$107.0 million in 2023, then surged by 195.78% to $102.5 million in 2024, then plunged by 170.48% to -$72.2 million in 2025, then jumped by 32.18% to -$49.0 million in 2026.
• Per Business Quant, the three latest RARE Cash from Investing Activities figures stand at -$49.0 million (Q1 2026), -$72.2 million (Q4 2025), and $117.2 million (Q3 2025).

Peer Comparison